₹4734.3▲0.4%
1.15%
Low
Day's Volatility:2.03%
High
0.88%
32.70%
Low
52 Weeks Volatility:49.29%
High
16.60%
Returns % | |
1 Month Return | -4.85 % |
3 Month Return | -6.37 % |
1 Year Return | 42.07 % |
Market Stats | |
Previous Close | ₹4,715.65 |
Open | ₹4,700.00 |
Volume | 1.20L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹56,605.66Cr |
based on 20 analysts
Based on 20 analysts offering long term price targets for Alkem Laboratories Ltd. An average target of ₹5170.25
Source: S&P Global Market Intelligence
Organisation | Alkem Laboratories Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Alkem Laboratories Ltd
Alkem Laboratories has managed to grow its earnings per share at 19% a year, which is close to the annualized share price gain of 22% per year. The TSR of Alkem Laboratories is 191% for the last 5 years, exceeding its share price return.
US FDA Issues Observations on Alkem's Baddi Unit; CFO Confident About Future Product Launches - 12 Apr, 2024
The US FDA has issued a report highlighting procedural errors at Alkem Laboratories' Baddi unit. While analysts believe an OAI classification is possible, the company's CFO remains confident about future product launches from other facilities.
USFDA Observations for Alkem Labs' Baddi Unit - 10 Apr, 2024
The US FDA has issued ten procedural observations to Alkem Laboratories' Baddi unit, including cleanliness and procedural errors. Shares of the company are trading slightly higher.
Alkem Laboratories Investigated by DGGI for Tax Credit and Exemption Issues - 02 Apr, 2024
The Directorate General of GST Intelligence (DGGI) is investigating Alkem Laboratories in two separate cases related to input tax credit and tax exemption issues. The company denies any wrongdoing and says it will settle fake input tax credit cases legally. The stock opened higher but closed lower, trading down 0.23% at Rs 4,993.15.
USFDA Inspection Results in Observations for Alkem Labs - 28 Mar, 2024
Alkem Laboratories' shares fell by nearly 3% after the US Food and Drug Administration (USFDA) issued a Form 483 with 10 observations for its manufacturing facility located in Baddi, Himachal Pradesh. The company received no data integrity observation and stated that the inspection was part of routine business operations. However, technical analysis suggests potential upside targets of 5200 and 5220.
Alkem Labs Receives Observations from US FDA Post Inspection - 27 Mar, 2024
Alkem Laboratories has received 10 observations from the US FDA following an inspection of its Baddi facility. The company stated that this is a routine business operation and will respond with a detailed plan within the stipulated timeline. Bernstein has maintained its outperform and underperform ratings on major pharmaceutical companies, including Alkem Laboratories.
Jan Aushadhi Scheme Dominates India's Rs 10,000-Crore Generics Market - 19 Mar, 2024
The Indian generics market worth Rs 10,000 crore is dominated by Cipla, Alkem, and the Jan Aushadhi scheme. The government-run scheme aims to provide quality medicines at affordable prices, up to 90% cheaper than regular prices.
Fundamentals of Alkem Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
FII Holding Up
Foreign Institutions have increased holdings from 6.03% to 8.49% in Dec 2023 quarter
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 54.0% return, outperforming this stock by 11.9%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 56.74% of holdings in Dec 2023 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 140.0% return, outperforming this stock by 67.8%
Retail Holding Down
Retail Investor have decreased holdings from 19.59% to 18.86% in Dec 2023 quarter
Price Dip
In the last 1 month, ALKEM stock has moved down by -4.9%
MF Holding Down
Mutual Funds have decreased holdings from 13.05% to 12.08% in Dec 2023 quarter
Profit Down
Netprofit is down for the last 2 quarters, 620.52 Cr → 594.96 Cr (in ₹), with an average decrease of 4.1% per quarter
Revenue Fall
Revenue is down for the last 2 quarters, 3.50K Cr → 3.41K Cr (in ₹), with an average decrease of 2.5% per quarter
Alkem Laboratories Ltd in the last 5 years
Lowest (20.07x)
March 24, 2021
Today (35.98x)
April 16, 2024
Industry (60.97x)
April 16, 2024
Highest (44.21x)
August 9, 2023
Funds | Holdings |
DSP Midcap Fund Direct Plan Growth | 4.05% |
Axis Midcap Fund Direct Plan Growth | 1.57% |
Nippon India Growth Fund - Direct Plan - Growth | 1.57% |
ICICI Prudential ELSS Tax Saver Fund Direct Plan Growth | 1.89% |
Kotak Emerging Equity Scheme Direct Growth | 0.59% |
Investors | Holdings % | Prev. 4 periods | 3M change |
---|---|---|---|
Promoter Holdings | 56.74% | 0.00 | |
Foreign Institutions | 8.49% | 40.65 | |
Mutual Funds | 12.08% | ||
Retail Investors | 18.86% | ||
Others | 3.83% |
Technicals of Alkem Laboratories Ltd share
News & Events of Alkem Laboratories Ltd
Alkem Laboratories Ltd (ALKEM) share price today is ₹4734.3
Alkem Laboratories Ltd is listed on NSE
Alkem Laboratories Ltd is listed on BSE
PE Ratio of Alkem Laboratories Ltd is 35.98
PE ratio = Alkem Laboratories Ltd Market price per share / Alkem Laboratories Ltd Earnings per share
Today’s traded volume of Alkem Laboratories Ltd(ALKEM) is 1.20L.
Today’s market capitalisation of Alkem Laboratories Ltd(ALKEM) is ₹56605.66Cr.
Alkem Laboratories Ltd(ALKEM | Price |
---|---|
52 Week High | ₹5520 |
52 Week Low | ₹3186.3 |
Alkem Laboratories Ltd(ALKEM) share price is ₹4734.3. It is down -14.23% from its 52 Week High price of ₹5520
Alkem Laboratories Ltd(ALKEM) share price is ₹4734.3. It is up 48.58% from its 52 Week Low price of ₹3186.3
Alkem Laboratories Ltd(ALKEM | Returns |
---|---|
1 Day Returns | 18.65% |
1 Month Returns | -4.85% |
3 Month Returns | -6.37% |
1 Year Returns | 42.07% |